Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.78 |
| ▸ | POLH | Q9Y253 | 4/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.51 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13941669 | 0.93 | ACE2 (0.78) | ACE2POLHADORA3ABCG2ABCB1 | |
| SCHEMBL12866476 | 0.92 | ACE2 (0.76) | ACE2POLHADORA3ABCG2ABCB1 | |
| SCHEMBL17620379 | 0.91 | ACE2 (0.94) | ACE2POLHADORA3ABCG2ABCB1 | |
| SCHEMBL12866635 | 0.91 | ACE2 (0.74) | ACE2POLHADORA3ABCG2ABCB1 | |
| SCHEMBL17620271 | 0.89 | ACE2 (0.83) | ACE2POLHADORA3ABCG2ABCB1 | |
| SCHEMBL17620268 | 0.87 | ACE2 (0.80) | ACE2POLHABCG2ABCB1ABCC1 | |
| SCHEMBL8737505 | 0.87 | ACE2 (0.79) | ACE2POLHADORA3ABCG2ABCB1 | |
| SCHEMBL13076849 | 0.86 | ACE2 (0.78) | ACE2POLHADORA3ABCG2ABCB1 | |
| SCHEMBL17620266 | 0.85 | ACE2 (0.77) | ACE2POLHADORA3ABCG2ABCB1 | |
| SCHEMBL15918780 | 0.84 | ACE2 (0.74) | ACE2POLHABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034413-A1 | NOVEL QUERCETIN DERIVATIVES AS ANTI-CANCER AGENTS | DABUR PHARMA LIMITED (IN) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034413-A1 | NOVEL QUERCETIN DERIVATIVES AS ANTI-CANCER AGENTS | TP53, ABCG2, RELA | ACE2 285/4885POLH 2309/4885ADORA3 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.